Brief: Adocia Announces Positive Topline Results For First Clinical Study Of ADO09

Adocia SA

09/04/2019 17:09

April 9 (Reuters) - ADOCIA SA  ADOC.PA :
    * ADOCIA ANNOUNCES POSITIVE TOPLINE RESULTS FOR THE FIRST
CLINICAL
STUDY OF ADO09, A NEW CO-FORMULATION OF PRAMLINTIDE AND A
PRANDIAL INSULIN ANALOG, IN PEOPLE WITH TYPE 1 DIABETES
    * ADO09 IS FIRST CO-FORMULATION OF PRAMLINTIDE AND
RAPID-ACTING
A21G HUMAN INSULIN ANALOG, METABOLITE OF INSULIN GLARGINE
    * ADO09 SHOWED A SIGNIFICANT 85% DECREASE IN BLOOD GLUCOSE
EXCURSION OVER FIRST TWO HOURS AFTER A MEAL COMPARED TO HUMALOG
    * ADO09 SHOWED SIMILAR GLUCOSE CONTROL OVER FIRST TWO HOURS
AFTER
A MEAL COMPARED TO SEPARATE INJECTIONS OF SYMLIN AND HUMULIN
    * ALL TREATMENTS WERE WELL TOLERATED
    * WE WILL NOW MOVE QUICKLY INTO A PHASE 2 CLINICAL TRIAL."
    * EXPECTS TO LAUNCH A PHASE 1/2, OUTPATIENT, 3-WEEK TRIAL OF
ADO09
DURING THIS QUARTER

Source text for Eikon:  ID:nBw8r6MMWa 
Further company coverage:  ADOC.PA 

 (Gdynia Newsroom)
 ((gdynia.newsroom@thomsonreuters.com;))